𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hyperglycemia as a symptom of neuroleptic malignant syndrome

✍ Scribed by M. Ishida; K. Otani; S. Kaneko; H. Ishida; S. Kawashima

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
185 KB
Volume
11
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

A 67-year-old schizophrenic woman developed neuroleptic malignant syndrome (NMS). She had mild diabetes mellitus, which had been controlled with diet therapy only. Upon the onset of NMS, hyperglycemia of up to 490 mg/dl developed. The hyperglycemia persisted during the NMS episode despite insulin treatment, and subsided only after the symptoms of NMS disappeared. The present report suggests that hyperglycemia may develop as a symptom of NMS, especially in patients with pre-existing impaired glucose tolerance, and that blood glucose should be monitored during NMS episodes.

KEY worms-neuroleptic malignant syndrome; hyperglycemia; central hypodopaminergic state

πŸ“œ SIMILAR VOLUMES

Paralytic ileus as a prodromal symptom o
Paralytic ileus as a prodromal symptom of the neuroleptic malignant syndrome
✍ Osamu Tanaka; Koichi Otani; Tsuyoshi Kondo; Sunao Kaneko; Yutaka Fukushima πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 229 KB

## Abstract A schizophrenic patient receiving neuroleptic treatment developed paralytic ileus followed by the neuroleptic malignant syndrome (NMS). The patient had previously experienced two NMS episodes, one of which was also accompanied by paralytic ileus. It is suggested that paralytic ileus can

Olanzapine associated weight gain, Hyper
Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report
✍ Rhonda Malyuk; Bruce Gibson; Ric M. Procyshyn; Nirmal Kang πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 47 KB

## Abstract We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year‐old woman with a significant medical history. Eighteen weeks after initiating olanzapine, Mrs X lost glycemic control, exhibited signs and symptoms consistent with

Neoplasia and the neuroleptic malignant
Neoplasia and the neuroleptic malignant syndrome
✍ P. W. R. Wooduff; E. Palazidou; I. Cranston; B. K. Toone; B. Summers; A. L. W. F πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 309 KB

## Abstract The association of neuroleptic malignant syndrome with neoplasia has not been previously reported. We report the case of a 64‐year‐old female patient who developed the classical picture of neuroleptic malignant syndrome in relation to a uterine leiomyosarcoma. This raises the question a

Treatment of neuroleptic malignant syndr
Treatment of neuroleptic malignant syndrome with levodopa
✍ K. Otani; K. Mihara; T. Kondo; M. Okada; S. Kaneko; Y. Fukushima πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 400 KB

Seven consecutive episodes of neuroleptic malignant syndrome in five cases were treated with 50-600 mg/day (mean 342 mg/day) of levodopa. In four episodes active pharmacological treatment was initiated with levodopa, while in the remaining three episodes it was introduced because of poor therapeutic

Olanzapine induced neuroleptic malignant
Olanzapine induced neuroleptic malignant syndromeβ€”a case review
✍ AleΕ‘ Kogoj; Ingrid Velikonja πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 79 KB

## Abstract Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders. Although potent neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs may also be a cause of NMS. Three databases were searched using the terms β€˜